Crosspoint Capital Strategies’s Pacira BioSciences PCRX Stock Holding History

Crosspoint Capital Strategies’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-151	Closed	-$11K	–	608
2014 Q1	$11K	Hold	151	–	–	﹤0.01%	463
2013 Q4	$12K	Buy	+151	New	+$7.94K	﹤0.01%	407

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Crosspoint Capital Strategies's PCRX Position: Q2 2014 in Review

Crosspoint Capital Strategies sold out of Pacira BioSciences (PCRX) in Q2 2014, closing a stake of 151 shares — an estimated $11K sold.

Crosspoint Capital Strategies first reported a position in PCRX in Q4 2013 and held it in 2 quarters. The position peaked at $12K in Q4 2013. 191 funds tracked by Wall St. Rank hold PCRX as of Q2 2014.

Crosspoint Capital Strategies reported no remaining Pacira BioSciences position as of Q2 2014 after selling out during the quarter.
Crosspoint Capital Strategies sold 151 Pacira BioSciences shares in Q2 2014, an estimated $11K.
Crosspoint Capital Strategies first reported a position in Pacira BioSciences in Q4 2013 and held it in 2 quarters.
Crosspoint Capital Strategies's Pacira BioSciences position peaked at $12K in Q4 2013.
191 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2014, filed 29 Jul 2014.